The folate antagonist methotrexate (MTX) is a drug currently used in the treatment of rheumatoid arthritis (RA). MTX enters the cells through the reduced folate carrier (RFC-1) and is activated to polyglutamates. Previous studies have shown that RFC-1 expression may influence the efficacy of therapy with MTX. The studies suggest that G80A polymorphism in RFC-1 is associated with altered folate/antifolate levels and the subjects carrying homozygous mutant 80AA genotype tend to have higher plasma folate and MTX concentrations and higher erythrocyte polyglutamate levels compared with those with the wild type or heterozygous genotype. It is possible that this polymorphism might influence MTX treatment outcome in patients with RA. In the present study, we examined the association between RFC-1 G80A polymorphism and treatment outcome in patients with RA administered MTX. The study was carried out on 174 patients diagnosed with RA treated with MTX (7.5-15.0 mg weekly) plus low doses of methylprednisone. The RFC-1 80G4A polymorphism (resulting in a histidine-to-arginine substitution at codon 27 of RFC-1) was detected using a polymerase chain reactionrestriction fragment length polymorphism method. The probability of remission of RA symptoms was 3.32-fold higher in carriers of 80AA genotype as compared with patients with 80GG genotype (P ¼ 0.021, OR ¼ 3.32,). The frequency of A allele among MTX responders was 62.1, compared to 47.8% in a group of poor MTX responders (P ¼ 0.013, OR ¼ 1.78, 95% CI: 1.13-2.81). Moreover, the increase of aminotransferase activity was noted more frequently in carriers of 80AA genotype. The present data suggest that evaluation of RFC-1 gene 80G4A polymorphism may be a useful tool to optimize MTX therapy in patients with RA.
Introduction
Methotrexate (MTX) is a folate antagonist first developed for treatment of malignancies and subsequently used in non-neoplastic diseases such as rheumatoid arthritis (RA). 1 The drug inhibits cell proliferation primarily by inhibiting de novo synthesis of purines and pyrimidines. MTX is taken up by cells via the reduced folate carrier (RFC) and then converted within the cells to polyglutamates. 2 MTX polyglutamates are long-living metabolites retaining some antifolate activities of the parent compound. The cellular formation of MTX polyglutamate plays a major role in cytotoxicity of MTX. Those poluglutamated derivates not only inhibit dihydrofolate reductase, the major MTX target, but also have markedly increased affinity for certain enzymes such as thymidylate synthase. 3 The RFC, an anion exchanger, is a 65 kDa transmembrane protein comprising 591 amino-acid residues, which transfers hydrophilic folates across the cell membrane using negatively charged glutamate residue of folate. In humans it exists in a highly glycosylated form with a mass of approximately 92 kDa. The gene coding for the human RFC protein is located on the long arm of chromosome 21, specifically the 21q22.2-q22.3 region. 4 Tolner et al. 5 studied cDNA from 16 genomic clones and obtained two overlapping sequences covering the RFC-1 gene. The first standard, labeled lhRFC-1-1, is a 19 kb segment containing exons 1, 2, 3 and 4. The second standard, lhRFC-1-2, is slightly shorter at 17 kb and contains exons 5 and 6. The 5 0 end of lhRFC-1-2 overlaps 1.5 kb of the 3 0 end of lhRFC-1-1, and thus together they cover 34.5 kb. The full-length cDNA was confirmed as the RFC-1 gene by transfection into MTXresistant cells, which have become resistant to this folate analog by producing a mutation in the protein and no longer take up MTX.
Recent studies have suggested that G80A polymorphism in RFC-1 is associated with altered folate/antifolate levels and may influence the efficacy of therapy with MTX. [6] [7] [8] In the present study, we examined the association between RFC-1 G80A polymorphism and treatment outcome in patients with RA administered MTX.
Results
The efficacy of RA therapy with MTX and methylprednisone is presented in In a group of 10 patients, an increase of aminotransferase activity (alanine transaminase (ALT), asparagine transaminase (AST)) above 100 UI during MTX therapy was noted, which resulted in discontinuation of treatment. Those adverse events were revealed in 10.8% of patients with 80AA genotype, in 5.3% with 80AG, and 2.3% with 80GG. The probability of those complications was fivefold higher in carriers of 80AA genotype compared with 80GG genotype patients (OR ¼ 5.09, 95% CI: 0.54-47.74). However, the difference did not reach statistical significance owing to the small number of cases (P ¼ 0.18) ( Table 2) .
Discussion
MTX used in high-dose therapy reaches extracellular concentrations (420 mmol/l) high enough to facilitate its simple diffusion across the cell membrane. When lower routine doses (e.g., as used in RA) are applied, the drug uses RFC-1 for transport into the cell to achieve effective intracellular concentrations. 9, 10 Previous studies have shown that downregulation of RFC-1 gene expression, modification of protein structure, and decreased MTX affinity to RFC protein were the most frequent mechanisms leading to MTX resistance and are associated with decreased MTX transmembrane transport into cells. The presence of mutations that downregulate expression of RFC-1 gene and produce transcriptional silencing underlay decreased activity of RFC-1 gene. 11, 12 Modification of the protein structure may be brought about by truncating mutations in MTX-resistant sublines. The truncated protein alone is unable to transport MTX and is correctly considered non-functional. 13 The decreased affinity of RFC protein to MTX may be brought 14 Thus, the transporter activity may be involved in therapeutic effects under MTX treatment and account for part of the large interpatient variability in response to MTX medication. Recent evidence suggests that G80A polymorphism in RFC-1 is associated with altered folate/antifolate levels and is modestly associated with the risk for neural tube defect. 10, 15, 16 Data suggest that subjects carrying the homozygous mutant 80AA genotype tend to have higher plasma folate and MTX levels and higher erythrocyte polyglutamate levels compared with those with the wild type or heterozygous genotype. 15, 17 In the present study, the influence of RFC-1 gene (G80A) polymorphism on treatment outcome with MTX of patients with RA was examined. The patients with RFC-1 AA genotype responded to the therapy more effectively than carriers of AG and GG genotypes. The remission of RA symptoms was significantly, that is, 3.32-fold, higher in 80AA carriers in comparison to 80GG individuals.
Similarly, in a series of studies carried out to determine the association of RFC-1 gene (G80A) polymorphism with MTX treatment outcome, Dervieux et al. 18 evaluated the influence of the polymorphism on MTX polyglutamate levels and MTX effects in RA patients. The authors observed increased concentrations of MTX polyglutamates in erythrocytes from patients with AA genotype. Higher concentrations of MTX polyglutamates in erythrocytes were associated with a lower score for physician's global assessment of the disease activity and lower score of patient's response to MTX. Remission of RA symptoms was also more frequently achieved in the carriers of the AA genotype. On the basis of the aforementioned results, as well as observations from the present study, it may be suggested that higher plasma folate and MTX concentrations and elevated erythrocyte MTX polyglutamate levels in patients with AA genotype may have contributed to lower disease activity and better treatment outcome during MTX therapy. However, the polymorphism could also directly impact disease activity through more subtle alteration in folate homeostasis. 15, 18 In our study hepatotoxicity, measured as ALT and AST activities, after MTX treatment was observed in some 4-5% of patients and more frequently affected individuals with RFC-1 80AA (10.5%) genotype than 80GG genotype (2.3%). An increased toxicity observed in this group of patients may be related to elevated levels of MTX polyglutamates seen in RFC-1 80AA individuals. 18 These observations are in keeping with previous studies, which demonstrated an association between increased MTX polyglutamate levels and hepatotoxic effects of the drug. 19, 20 In a previous study Laverdiere et al. 8 suggested an influence of RFC-1 gene (G80A) polymorphism on MTX plasma levels and treatment outcome of childhood acute lymphoblastic leukemia. In contrast to RA patients, children with 80AA genotype had worse prognoses than patients with 80GG genotype, and 80AA genotype was associated with higher plasma levels of MTX than other genotypes. One possible explanation for the observed association might be the decreased MTX concentrations in lymphoblastic cells in carriers of 80AA genotype despite higher plasma MTX levels.
The present data do suggest that evaluation of RFC-1 gene 80G4A polymorphism may be a useful tool to optimize MTX therapy in patients with RA. The evidence advocates additional studies aimed at identifying genetic factors associated with MTX treatment outcome.
Materials and methods

Patients
The study was carried out on 174 patients (129 women, 45 men, aged 21-70 years, disease duration 7.974.7 years) diagnosed with RA, treated with MTX (7.5-15.0 mg weekly) plus low doses of MP.
The RA was diagnosed according to the criteria of the American College of Rheumatology (ACR). All patients underwent a monthly evaluation for one year, applying the 1995 ACR preliminary definition of improvement in RA. Clinical improvement was evaluated according to the ACR 20% response criteria. The ACR core set of variables included the number of swollen joints, the number of tender joints, physician's global assessment of disease activity on a 0 to 10 scale, patient's global assessment of disease activity on a 0 to 10 scale, patient's assessment of pain on a 100-mm visual analog scale (VAS), and the functional status of patients using the Health Assessment Questionnaire (HAQ) scored on a 0-3 scale. A 28-joint count (including the metacarpophalangeal joints, the proximal interphalangeal joints, wrists and elbows) was used. 21, 22 A patient was classified as a good responder when both the tender joint count and the swollen joint count were X20% improved from baseline and at least three of the following criteria were met: X20% improvement in VAS, in erythrocyte sedimentation rate (ESR), in physician's global assessment of disease activity, in patient's global assessment of disease activity, and in HAQ. The group 'good responders' included patients in remission for at least 6 months. 23, 24 The second group 'poor responders' included patients with active disease despite of at least 6 months of therapy with MTX.
The study was approved by the local ethics committee, and written informed consent was obtained from all subjects.
Genotyping
Genomic DNA was extracted manually (precipitation with trimethylammonium bromide salts from leukocytes contained in 450 ml of venous blood with ethylene diamine tetraacetic acid as an anticoagulant). DNA was then precipitated in 95% ethanol, dissolved in distilled water, and stored at À201C until analysis. The RFC-1 80G4A polymorphism (resulting in a histidine-to-arginine substitution at codon 27 of RFC-1) was detected using a polymerase chain reaction-restriction fragment length polymorphism method, as described previously.
Statistical analysis
The associations between categorical variables were assessed by w 2 -test and Fisher's exact test, using Statistica 6.0 (Statsoft). Odds ratios and confidence intervals were calculated using the Newcombe-Wilson method without continuity correction.
